Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-ß-Lactamase Inhibitor Combination.
Antimicrob Agents Chemother
; 59(8): 5036-9, 2015 Aug.
Article
em En
| MEDLINE
| ID: mdl-26014937
ABSTRACT
Ceftazidime-avibactam is a broad-spectrum-ß-lactamase inhibitor combination in late-stage clinical development for the treatment of serious infections. In preparation for clinical microbiology laboratory use, a validation experiment was initiated to evaluate a commercial broth microdilution product (Sensititre dried MIC susceptibility system) compared to reference panels using 525 recent clinical isolates. Among 11 pathogen groups, all had Sensititre MIC/reference MIC ratios predominantly at 1 (47.5% to 97.5%), and automated and manual endpoint results did not differ. Enterobacteriaceae MIC comparisons showed a modest skewing of Sensititre MIC results toward an elevated MIC (33.9%), but the essential agreement was 98.9% with 100.0% reproducibility. In conclusion, Sensititre panels produced accurate ceftazidime-avibactam MIC results, allowing quality MIC guidance for therapy following regulatory approvals.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pseudomonas aeruginosa
/
Ceftazidima
/
Enterobacteriaceae
/
Compostos Azabicíclicos
/
Inibidores de beta-Lactamases
/
Bactérias Gram-Positivas
/
Antibacterianos
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article